IL-11Rα: a novel target for the treatment of osteosarcoma.

Valerae O Lewis

Journal: Advances in experimental medicine and biology 2014;804():285-9

PMID: 24924180

Abstract

Recent advances have shown that cell surface receptors are expressed differentially in normal and pathological conditions. Novel organ specific and disease specific proteins expressed on tumor vasculature have been identified by in vivo phage display technology and the diversity of the tumor-associated vasculature has provided the basis for the development of targeted therapeutics. Investigators recently screened a phage display library in a human cancer patient. An IL-11 mimic phage displaying the cyclic peptide CGRRAGGSC (single letter amino acid code) specifically bound to immobilized IL-11Rα. It has been demonstrated that the expression of the IL-11Rα is increased in several other types of tumors including osteosarcoma. The ability to selectively target the IL-11Rα may provide an alternative treatment of for a disease where new treatment options are truly needed.

Address: Department of Orthopaedic Oncology, MD Anderson Cancer Center, 301402, Unit 1448, Houston, TX, 77230-1402, USA, [email protected].

DOI: 10.1007/978-3-319-04843-7_15

Link outs

Free resources

Medical:

https://medlineplus.gov/bonecancer.html

Other Literature Sources:

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/978-3-319-04843-7_15

MeSH Terms: Antineoplastic Agents, Bone Neoplasms, Cell Engineering, Gene Expression, Humans, Immunotherapy, Lung Neoplasms, Molecular Targeted Therapy, Neovascularization, Pathologic, Osteosarcoma, Peptide Library, Peptides, Cyclic, Receptors, Interleukin-11, Signal Transduction, T-Lymphocytes, Cytotoxic